Neurovascular Embolization Devices - Market Insights, Competitive Landscape, and Market Forecast - 2032

Neurovascular Embolization Device Market by Product Type (Embolization Coils, Neurovascular Coil Assist Devices [Coil Assist Stents and Coil Assist Balloons], Liquid Embolization Systems, Flow Diversion Stents, Intrasaccular Flow Disruptor, and Others), By End-User (Hospitals, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the growing prevalence of neurovascular disorders, increase in prevalence of hypertension across the globe, and increase in product development activities by the key market players across the globe.

The neurovascular embolization devices market was valued at USD 1,347.66 million in 2024, growing at a CAGR of 4.40% during the forecast period from 2025 to 2032, to reach USD 1,890.84 million by 2032. The rising prevalence of neurovascular disorders such as aneurysms, severe head injuries, sedentary lifestyles, and ischemic strokes is significantly driving the global market for neurovascular embolization devices. These conditions often require precise, minimally invasive treatments, for which embolization devices are critical. Additionally, the global increase in hypertension a major risk factor for neurovascular diseases has led to a higher incidence of brain hemorrhages and aneurysms, further fueling demand for effective embolization solutions.

Ongoing product development efforts by key market players are introducing advanced and efficient embolization devices, improving patient outcomes and procedural success rates. Innovations in device design, biocompatibility, and delivery mechanisms are enhancing treatment precision and safety, thereby expanding adoption among healthcare providers.

Collectively, these factors are expected to drive substantial growth in the global neurovascular embolization devices market during the forecast period from 2025 to 2032.

Neurovascular Embolization Devices Market Dynamics:

According to the Global Burden of Disease (2024), neurological conditions affected approximately 43% of the global population in 2021, impacting around 3.4 billion individuals. Among these, tension-type headaches were the most prevalent, with an estimated 2 billion cases, followed by migraines affecting approximately 1.1 billion people. Additionally, the global prevalence of diabetic neuropathy has more than tripled since 1990, reaching 206 million cases in 2021. Chronic tension headaches often have vascular implications, while diabetic neuropathy can lead to vascular damage, increasing the risk of neurovascular conditions such as aneurysms and arteriovenous malformations (AVMs). As the incidence of these neurological disorders rises, the demand for minimally invasive treatments to mitigate the risks of stroke and other vascular complications is growing. Neurovascular embolization devices used to block abnormal blood flow or seal aneurysms play an increasingly vital role in addressing these conditions, thereby driving global market growth.

Complementing these trends, the British Heart Foundation (2024) reported that approximately 56 million women and 45 million men worldwide were stroke survivors. Strokes, often caused by blood clots, aneurysms, or abnormal blood vessel formations in the brain, require prompt intervention to restore blood flow and prevent hemorrhagic events. Neurovascular embolization devices including coils, stents, and liquid embolic agents are essential in treating these conditions by sealing aneurysms, preventing vessel ruptures, and blocking abnormal blood flow to damaged brain tissue, further propelling market expansion.

In addition to rising disease prevalence, increasing product development activities are expected to bolster market growth. For instance, in April 2021, Medtronic plc received FDA approval for its Pipeline™ Flex Neurovascular Embolization Device with Shield Technology™, designed to reduce thrombogenicity and lower the risk of clot formation during flow diversion therapy.

Despite these growth drivers, certain challenges may impede market progress. Complications associated with embolization procedures such as aneurysmal perforations caused by micro catheters, micro-guidewires, or coils pose procedural risks. Moreover, stringent regulatory approval processes can delay product launches, potentially restraining market growth.

Neurovascular Embolization Devices Market Segment Analysis:

Neurovascular Embolization Device Market by Product Type (Embolization Coils, Neurovascular Coil Assist Devices [Coil Assist Stents and Coil Assist Balloons], Liquid Embolization Systems, Flow Diversion Stents, Intrasaccular Flow Disruptor, and Others), By End-User (Hospitals, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the product type segment of the global neurovascular embolization devices market, embolization coils are projected to hold the largest share in 2024. These coils, typically made from platinum or other biocompatible materials, are inserted into aneurysms to promote clot formation, effectively sealing the aneurysm and preventing rupture. As a minimally invasive alternative to open surgery, embolization coils offer patients faster recovery times and lower complication risks, making them a preferred choice in neurovascular procedures.

Technological advancements such as improved coil flexibility, enhanced precision, and better radiopacity have further driven their adoption in both emergency and elective neurovascular treatments. These innovations enable physicians to navigate complex vascular anatomies more efficiently, improving procedural success rates and patient outcomes.

Moreover, increased funding for the development and commercialization of neurovascular embolization coils is contributing to market growth. For example, in July 2021, Zylox-Tonbridge Medical Technology Co., Ltd. raised USD 329 million to support the development of its core neurovascular products, including embolization coils and micro catheters for coiling procedures.

Collectively, these factors are expected to generate significant revenue for the embolization coil segment, driving the overall growth of the global neurovascular embolization devices market during the forecast period.

North America is expected to dominate the overall neurovascular embolization devices market:

North America is projected to hold the largest share of the global neurovascular embolization devices market in 2024. The region’s market growth is primarily driven by the high prevalence of neurovascular disorders such as aneurysms, hypertension, and hemorrhages coupled with increasing product development activities and supportive government initiatives. These factors are expected to significantly contribute to market expansion during the forecast period (2025 to 2032).

According to the Brain Aneurysm Foundation (2024), an estimated 6.8 million people in the United States approximately 1 in 50 individuals were living with an unruptured brain aneurysm in 2021. The annual rupture rate ranged from 8 to 10 per 100,000 people, with approximately 30,000 aneurysm ruptures occurring each year, translating to one rupture every 18 minutes. This growing diagnosis rate of both ruptured and unruptured aneurysms underscores the need for advanced, minimally invasive treatment solutions. Neurovascular embolization devices including coils, flow diverters, and stents are pivotal in preventing aneurysm ruptures and managing bleeding, offering safer alternatives to traditional open surgeries.

Similarly, the prevalence of strokes further escalates market demand. As per the Centers for Disease Control and Prevention (CDC, 2024), a stroke occurs every 40 seconds in the United States, affecting over 795,000 individuals annually. Of these, approximately 610,000 are first-time strokes, while around 185,000 occur in individuals with a prior stroke. Ischemic strokes caused by blocked blood flow to the brain account for about 87% of these cases. With hypertension being a leading risk factor for both ischemic and hemorrhagic strokes, the growing hypertensive population elevates the incidence of aneurysms, arteriovenous malformations (AVMs), and other neurovascular conditions. Consequently, this drives the need for neurovascular embolization devices to effectively manage and treat these conditions.

Government initiatives aimed at improving brain aneurysm research are further propelling market growth. For example, in March 2021, during the 117th Congressional Session, the U.S. government allocated USD 10 million annually from 2022 to 2030 to support comprehensive research on unruptured intracranial aneurysms, with funds available through September 30, 2029. Such funding is instrumental in fostering technological advancements and improving patient care.

In conclusion, the combination of a high disease burden, technological advancements, supportive policy measures, and increased public awareness is expected to bolster the North American neurovascular embolization devices market during the forecast period.

Neurovascular Embolization Devices Market Key Players:

Some of the key market players operating in the neurovascular embolization devices market include Medtronic PLC, Stryker, MicroVention, Inc. (Terumo Corporation), Johnson & Johnson Services, Inc., Penumbra, Inc., B. Braun Melsungen AG, Acandis GmbH, Wallaby Medical., Shape Memory Medical Inc., Zylox-Tonbridge Medical Technology Co., Ltd., Spartan Micro, Inc., KANEKA CORPORATION, Lepu Medical Technology(Beijing)Co., Ltd., Meril Life Sciences Pvt. Ltd., Boston Scientific Corporation, phenox GmbH, Merit Medical Systems., Perflow Medical Ltd., MicroPort Scientific Corporation., Cerus Endovascular, and others.

Recent Developmental Activities in the Neurovascular Embolization Devices Market:

In July 2024, MicroVention, Inc., a neurovascular company and subsidiary of Terumo Corporation, announced the publication of the CLEVER trial results. This multicenter, prospective study involved 163 patients across 17 European centers. Investigators assessed the safety and effectiveness of MicroVention’s Woven EndoBridge (WEB) 17 system for treating ruptured and unruptured aneurysms. The WEB 17 is the company’s newest and smallest aneurysm embolization system.

Key Takeaways from the Neurovascular Embolization Devices Market Report Study:

Market size analysis for current neurovascular embolization devices size (2024), and market forecast for 8 years (2025 to 2032)

Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.

Key companies dominating the neurovascular embolization devices market.

Various opportunities available for the other competitors in the neurovascular embolization devices market space.

What are the top-performing segments in 2024? How these segments will perform in 2032?

Which are the top-performing regions and countries in the current neurovascular embolization devices market scenario?

Which are the regions and countries where companies should have concentrated on opportunities for neurovascular embolization devices market growth in the coming future?

Target Audience Who Can be Benefited from this Neurovascular Embolization Devices Market Report Study:

Neurovascular embolization device providers

Research organizations and consulting companies

Neurovascular embolization devices -related organizations, associations, forums, and other alliances

Government and corporate offices

Start-up companies, venture capitalists, and private equity firms

Distributors and traders dealing in neurovascular embolization devices

Various end-users who want to know more about the neurovascular embolization devices market and the latest technological developments in the neurovascular embolization devices market.

Frequently Asked Questions for the Neurovascular Embolization Devices Market:

1. What are neurovascular embolization devices?

A neurovascular embolization device is an intravascular implant intended to permanently occlude blood flow to cerebral aneurysms and cerebral arteriovenous malformations.

2. What is the market for neurovascular embolization devices?

The neurovascular embolization devices market was valued at USD 1,3477.66 million in 2024, growing at a CAGR of 4.40% during the forecast period from 2025 to 2032, to reach USD 1,890.84 million by 2032.

3. What are the drivers for the neurovascular embolization devices market?

The growing prevalence of neurovascular disorders, such as aneurysms, severe head injuries, sedentary lifestyles, and ischemic strokes, is significantly boosting the market for neurovascular embolization devices. Additionally, the global rise in hypertension, a major risk factor for neurovascular diseases, has increased the number of patients susceptible to conditions like brain hemorrhages and aneurysms, thus driving the demand for effective embolization devices. Furthermore, increased product development activities by key market players across the globe are introducing more advanced and efficient embolization solutions, improving outcomes for patients and enhancing procedural success. Together, these factors are expanding the global market for neurovascular embolization devices.

4. Who are the key players operating in the neurovascular embolization devices market?

Some of the key market players operating in the neurovascular embolization devices market include Medtronic PLC, Stryker, MicroVention, Inc. (Terumo Corporation), Johnson & Johnson Services, Inc., Penumbra, Inc., B. Braun Melsungen AG, Acandis GmbH, Wallaby Medical., Shape Memory Medical Inc., Zylox-Tonbridge Medical Technology Co., Ltd., Spartan Micro, Inc., KANEKA CORPORATION, Lepu Medical Technology(Beijing)Co., Ltd., Meril Life Sciences Pvt. Ltd., Boston Scientific Corporation, phenox GmbH, Merit Medical Systems., Perflow Medical Ltd., MicroPort Scientific Corporation., Cerus Endovascular, and others.

5. Which region has the highest share in the neurovascular embolization devices market?

Among all the regions, North America is expected to hold the largest share of the global neurovascular embolization devices market in 2024. The growing prevalence of neurovascular disorders, such as aneurysms, hypertension, hemorrhages, and others is expected to boost the market across the region. Additionally, recent product developmental activities and rising government initiatives are expected to aid in the growth of the North American neurovascular embolization devices market during the forecast period from 2025 to 2032.